Life-Changing Gene Therapy Restores Vision for Young Girl in the UK

A remarkable advancement in gene therapy has provided a young girl in the UK with the gift of sight, transforming her daily life and offering hope to many families facing similar challenges. Saffie Sandford, a 6-year-old from Stevenage, has successfully regained her ability to see normally, both during the day and at night, after receiving a groundbreaking treatment for a rare form of congenital blindness known as Leber’s Congenital Amaurosis (LCA).

Innovative Treatment Brings Sight to Life

Diagnosed with LCA, Saffie's vision was severely impaired due to a mutation in the RPE 65 gene that both her parents unknowingly carried. LCA typically manifests as the inability to see in low light and provides challenges in daylight visibility, leading to a progressive worsening of sight from birth. Fortunately, Great Ormond Street Hospital (GOSH) in London had developed an innovative gene therapy—Luxturna—specifically designed to combat this condition. This therapy delivers a healthy copy of the RPE 65 gene directly into the patient’s eyes in a single dose.

A New Beginning for Saffie

Following her first treatment in April 2025 and a subsequent dose in September, Saffie's mother, Lisa, described the transformation as life-changing: "It’s like someone waved a magic wand and restored her sight in the dark." With the new therapy, Saffie can now participate in activities such as trick-or-treating and dining out in the evening—experiences that were previously impossible.

Promising Results and Future Implications

GOSH has recently published a study highlighting the effects of Luxturna, showing that the treatment resulted in significant vision improvements for many children aged between 15 months and 12 years who suffer from LCA. Remarkably, 7 out of 10 children exhibited clinically meaningful improvements, indicating the therapy's potential to change lives. The evidence also incorporated novel testing methods to measure visual pathway strength in infants, offering more insights into the effectiveness of gene therapy.

Rob Henderson, a consultant ophthalmologist at GOSH, remarked on the significance of these findings: "For many families, even small improvements in their child's ability to see the world around them make a profound difference." This groundbreaking treatment not only offers a new lease on life for Saffie but also opens doors for many other children affected by similar conditions.